Schwab Charles Investment Management Inc. increased its holdings in shares of Flexion Therapeutics Inc (NASDAQ:FLXN) by 6.3% in the third quarter, Holdings Channel reports. The institutional investor owned 107,550 shares of the specialty pharmaceutical company’s stock after purchasing an additional 6,336 shares during the quarter. Schwab Charles Investment Management Inc.’s holdings in Flexion Therapeutics were worth $2,601,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. Advisor Group Inc. increased its stake in Flexion Therapeutics by 205.9% in the second quarter. Advisor Group Inc. now owns 5,200 shares of the specialty pharmaceutical company’s stock valued at $105,000 after purchasing an additional 3,500 shares in the last quarter. SG Americas Securities LLC bought a new stake in Flexion Therapeutics in the third quarter valued at approximately $135,000. IFP Advisors Inc increased its stake in Flexion Therapeutics by 58.1% in the third quarter. IFP Advisors Inc now owns 8,030 shares of the specialty pharmaceutical company’s stock valued at $194,000 after purchasing an additional 2,950 shares in the last quarter. State Board of Administration of Florida Retirement System bought a new stake in Flexion Therapeutics in the third quarter valued at approximately $235,000. Finally, Voya Investment Management LLC increased its stake in Flexion Therapeutics by 25.8% in the second quarter. Voya Investment Management LLC now owns 12,914 shares of the specialty pharmaceutical company’s stock valued at $261,000 after purchasing an additional 2,651 shares in the last quarter. 72.78% of the stock is owned by hedge funds and other institutional investors.

In other Flexion Therapeutics news, insider Neil Bodick bought 2,700 shares of Flexion Therapeutics stock in a transaction that occurred on Tuesday, November 21st. The stock was acquired at an average price of $24.49 per share, for a total transaction of $66,123.00. Following the completion of the acquisition, the insider now owns 64,605 shares of the company’s stock, valued at approximately $1,582,176.45. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Michael D. Clayman bought 5,000 shares of Flexion Therapeutics stock in a transaction that occurred on Wednesday, November 8th. The shares were acquired at an average price of $23.60 per share, with a total value of $118,000.00. Following the acquisition, the insider now directly owns 35,395 shares of the company’s stock, valued at approximately $835,322. The disclosure for this purchase can be found here. 15.98% of the stock is owned by corporate insiders.

Several equities research analysts have commented on FLXN shares. Janney Montgomery Scott upped their target price on shares of Flexion Therapeutics to $570.00 and gave the company a “fair value” rating in a research note on Tuesday, October 10th. Wells Fargo & Co set a $39.00 target price on shares of Flexion Therapeutics and gave the company a “buy” rating in a research note on Friday, October 6th. Zacks Investment Research downgraded shares of Flexion Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, October 17th. Royal Bank of Canada set a $44.00 price objective on shares of Flexion Therapeutics and gave the stock a “buy” rating in a research report on Sunday, October 29th. Finally, Northland Securities reissued a “buy” rating and set a $40.00 price objective on shares of Flexion Therapeutics in a research report on Wednesday, October 4th. Three research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $106.25.

Shares of Flexion Therapeutics Inc (FLXN) opened at $23.63 on Thursday. The company has a current ratio of 12.93, a quick ratio of 12.93 and a debt-to-equity ratio of 0.87. Flexion Therapeutics Inc has a 12-month low of $16.51 and a 12-month high of $32.25. The stock has a market cap of $939.65, a price-to-earnings ratio of -6.73 and a beta of 1.15.

Flexion Therapeutics (NASDAQ:FLXN) last issued its quarterly earnings data on Monday, November 6th. The specialty pharmaceutical company reported ($1.07) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.98) by ($0.09). research analysts expect that Flexion Therapeutics Inc will post -3.84 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Schwab Charles Investment Management Inc. Acquires 6,336 Shares of Flexion Therapeutics Inc (FLXN)” was first reported by Daily Political and is owned by of Daily Political. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of US and international trademark and copyright laws. The legal version of this story can be read at https://www.dailypolitical.com/2018/01/18/schwab-charles-investment-management-inc-acquires-6336-shares-of-flexion-therapeutics-inc-flxn.html.

Flexion Therapeutics Company Profile

Flexion Therapeutics, Inc is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company’s lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid.

Want to see what other hedge funds are holding FLXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Flexion Therapeutics Inc (NASDAQ:FLXN).

Institutional Ownership by Quarter for Flexion Therapeutics (NASDAQ:FLXN)

Receive News & Ratings for Flexion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.